A pan-cancer analysis reveals CHD1L as a prognostic and immunological biomarker in several human cancers
Introduction: Several recent studies pointed out that chromodomain-helicase-DNA-binding protein 1-like (CHD1L) is a putative oncogene in many human tumors. However, up to date, there is no pan-cancer analysis performed to study the different aspects of this gene expression and behavior in tumor tiss...
Main Authors: | Mohamed A. Soltan, Muhammad Alaa Eldeen, Refaat A. Eid, Najiah M. Alyamani, Leena S. Alqahtani, Sarah Albogami, Ibrahim Jafri, Moon Nyeo Park, Ghadi Alsharif, Eman Fayad, Gamal Mohamed, Rihab Osman, Bonglee Kim, Mohamed Samir A. Zaki |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-03-01
|
Series: | Frontiers in Molecular Biosciences |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmolb.2023.1017148/full |
Similar Items
-
Integrative analysis of WDR12 as a potential prognostic and immunological biomarker in multiple human tumors
by: Refaat A. Eid, et al.
Published: (2023-01-01) -
The validation of new CHD1L inhibitors as a therapeutic strategy for cancer
by: Sophia Clune, et al.
Published: (2024-01-01) -
CHD2-Related CNS Pathologies
by: Marc-Michel Wilson, et al.
Published: (2021-01-01) -
CHD1, a multifaceted epigenetic remodeler in prostate cancer
by: Haoyan Li, et al.
Published: (2023-01-01) -
Materials of the congress CHD and peripheral atherosclerosis treatment in diabetic patients
by: Victor Yur'evich Kalashnikov, et al.
Published: (2012-03-01)